Stockscreener 앱 받기
13.66
4.42%
0.58
Arcutis Biotherapeutics Inc 주식(ARQT)의 최신 뉴스
Objective long/short (ARQT) Report - Stock Traders Daily
Short Interest in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Decreases By 9.3% - MarketBeat
Arcutis Biotherapeutics (NASDAQ:ARQT) Trading Down 4%Time to Sell? - MarketBeat
Wall Street Analysts Believe Arcutis Biotherapeutics (ARQT) Could Rally 37.43%: Here's is How to Trade - Yahoo Finance
Arcutis Biotherapeutics’ (ARQT) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Arcutis stock target lifted, buy rating held on significant developments By Investing.com - Investing.com South Africa
Arcutis Biotherapeutics (NASDAQ:ARQT) Shares Gap UpStill a Buy? - MarketBeat
Arcutis stock target lifted, buy rating held on significant developments - Investing.com India
Arcutis Biotherapeutics' (ARQT) Buy Rating Reiterated at HC Wainwright - MarketBeat
Demystifying Arcutis Biotherapeutics: Insights From 5 Analyst Reviews - Benzinga
JPMorgan Chase & Co. Raises Stake in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - Defense World
Arcutis Shares Climb on Strong Product Revenue Estimates - MarketWatch
Why Sage Therapeutics Shares Are Trading Higher By Over 34%; Here Are 20 Stocks Moving Premarket - Benzinga
Arcutis Biotherapeutics, Inc. Announces Preliminary Unaudited Earnings Guidance for Fourth Quarter and Full Year 2024 - Marketscreener.com
Arcutis Announces Preliminary Unaudited Fourth Quarter Product Revenue and Full-Year 2024 Product Revenues of Approximately $63 Million and $160 Million - The Manila Times
Arcutis Q4 Revenue Surges 366% to $63M as ZORYVE Demand Accelerates Across Indications - StockTitan
Rajvir Madan Joins Arcutis as Chief Digital and Information Officer -June 01, 2021 at 07:30 am EDT - Marketscreener.com
Arcutis Biotherapeutics (NASDAQ:ARQT) Trading Down 8.5%Here's What Happened - MarketBeat
Commit To Purchase Arcutis Biotherapeutics At $7.50, Earn 21.3% Using Options - Nasdaq
Arcutis Biotherapeutics (NASDAQ:ARQT) Stock Price Expected to Rise, Mizuho Analyst Says - Defense World
When the Price of (ARQT) Talks, People Listen - Stock Traders Daily
Mizuho Forecasts Strong Price Appreciation for Arcutis Biotherapeutics (NASDAQ:ARQT) Stock - MarketBeat
Arcutis Biotherapeutics (NASDAQ:ARQT) Sets New 52-Week HighHere's What Happened - MarketBeat
Arcutis stock soars to 52-week high, hits $15.85 amid robust gains - Investing.com
Mizuho lifts Arcutis stock price target to $20, maintains Outperform By Investing.com - Investing.com Australia
Arcutis Biotherapeutics director Welgus sells $146,714 in stock By Investing.com - Investing.com Nigeria
Mizuho lifts Arcutis stock price target to $20, maintains Outperform - Investing.com
Insider Selling: Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Director Sells 10,000 Shares of Stock - MarketBeat
Arcutis Biotherapeutics director Welgus sells $146,714 in stock - Investing.com
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Arcutis Biotherapeutics Grants 75,500 RSUs to New Hires in Strategic Talent Acquisition Move - StockTitan
Here's Why Arcutis Stock More Than Doubled In Market Value In One Year - Barchart
Here's Why Arcutis Stock More Than Doubled in Market Value in One Year - MSN
Arcutis Biotherapeutics (NASDAQ:ARQT) Trading 7% HigherHere's Why - MarketBeat
Is Arcutis Biotherapeutics (NASDAQ:ARQT) A Risky Investment? - Simply Wall St
What is HC Wainwright’s Forecast for ARQT FY2024 Earnings? - Defense World
FY2024 Earnings Estimate for ARQT Issued By HC Wainwright - MarketBeat
Arcutis Biotherapeutics CMO Patrick Burnett sells shares for $23,674 By Investing.com - Investing.com Nigeria
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Insider Patrick Burnett Sells 1,691 Shares - MarketBeat
Arcutis Biotherapeutics CMO Patrick Burnett sells shares for $23,674 - Investing.com India
Looking Ahead to 2025 Dermatology Drug Approvals - Dermatology Times
H.C. Wainwright initiates Buy on Arcutis Biotherapeutics shares highlighting Zoryve potential - Investing.com Canada
HC Wainwright & Co. Initiates Coverage of Arcutis Biotherapeutics (ARQT) with Buy Recommendation - MSN
0.98%
7.55%
자본화:
|
볼륨(24시간):